shr-1314
Showing 1 - 8 of 8
Active Moderate to Severe Graves' Orbitopathy Trial (SHR-1314)
Not yet recruiting
- Active Moderate to Severe Graves' Orbitopathy
- SHR-1314
- (no location specified)
May 23, 2022
Ankylosing Spondylitis Trial in Beijing (SHR-1314, Placebo)
Recruiting
- Ankylosing Spondylitis
- SHR-1314
- Placebo
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Jun 22, 2021
Lupus Nephritis Trial (SHR-1314, Placebo)
Not yet recruiting
- Lupus Nephritis
- SHR-1314
- Placebo
- (no location specified)
Jun 7, 2021
Moderate-to-Severe Plaque Psoriasis Trial (SHR-1314, Placebo)
Not yet recruiting
- Moderate-to-Severe Plaque Psoriasis
- SHR-1314
- Placebo
- (no location specified)
Apr 8, 2021
Bioequivalence Trial (SHR-1314)
Unknown status
- Bioequivalence
- SHR-1314
- (no location specified)
Aug 23, 2020
Pharmacokinetic Trial (SHR-1314)
Unknown status
- Pharmacokinetic
- SHR-1314
- (no location specified)
Mar 26, 2020
Moderate-to-severe Chronic Plaque Psoriasis Trial in Australia, China, United States (SHR-1314, Placebo)
Unknown status
- Moderate-to-severe Chronic Plaque Psoriasis
- SHR-1314
- Placebo
-
Phoenix, Arizona
- +12 more
Jan 2, 2019
Psoriasis Trial in Sydney (SHR-1314, )
Completed
- Psoriasis
- SHR-1314
- placebo
-
Sydney, New South Wales, AustraliaAtridia Pty Limited
Nov 13, 2017